Results 1 to 10 of about 20,717 (141)

In vitro and in vivo acaricidal properties of orally delivered ivermectin against the blacklegged tick, Ixodes scapularis [PDF]

open access: yesParasites & Vectors
Background The lack of effective and affordable new environmental tick control products is one of the major challenges to the existing control strategies against the blacklegged tick (Ixodes scapularis), the vector of Lyme disease affecting public health
Jolieke G. van Oosterwijk   +3 more
doaj   +2 more sources

A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

open access: yesInternational Journal of Infectious Diseases, 2021
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro.
Jyoti Somani   +2 more
exaly   +3 more sources

Efficacy of ivermectin for malaria vector control: a systematic review and meta-analysis of randomized clinical trials [PDF]

open access: yesMalaria Journal
Background Despite global malaria control efforts, malaria continues to cause approximately 241–249 million cases and over 600,000 deaths annually. Ivermectin, a broad-spectrum antiparasitic drug with endectocidal activity against mosquitoes feeding on ...
Shrouk Ramadan   +11 more
doaj   +2 more sources

Acute toxicity events of ivermectin in chicks’ model [PDF]

open access: yesIraqi Journal of Veterinary Sciences, 2022
Ivermectin is a very safe drug; however, there are many studies on its toxic effects in different animals due to sensitivity, misuse, or accidental overdose.
Tamara K. Al-Najmawi, Muna H. Al-Zubaidy
doaj   +1 more source

In vitro larvicidal activity of ivermectin and povidone-iodine against Oestrus ovis.

open access: yesPLoS ONE, 2021
PurposeTo assess the in vitro larvicidal activity of ivermectin and povidone-iodine (PVP-I) against Oestrus ovis, the most frequent cause of external ophthalmomyiasis.MethodsL1 O.
Giuseppe D'Amico Ricci   +6 more
doaj   +2 more sources

Ivermectin metabolites reduce Anopheles survival

open access: yesScientific Reports, 2023
Ivermectin mass drug administration to humans or livestock is a potential vector control tool for malaria elimination. The mosquito-lethal effect of ivermectin in clinical trials exceeds that predicted from in vitro laboratory experiments, suggesting ...
Kevin C. Kobylinski   +14 more
doaj   +1 more source

Current therapeutic applications and pharmacokinetic modulations of ivermectin [PDF]

open access: yesVeterinary World, 2019
Ivermectin is considered to be a wonder drug due to its broad-spectrum antiparasitic activity against both ectoparasites and endoparasites (under class of endectocide) and has multiple applications in both veterinary and human medicine.
Khan Sharun   +5 more
doaj   +1 more source

Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes

open access: yesMalaria Journal, 2023
Background Ivermectin (22,23-dihydroavermectin B1a: H2B1a) is an endectocide used to treat worm infections and ectoparasites including lice and scabies mites.
Charlotte Kern   +5 more
doaj   +1 more source

Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer

open access: yesCell Death and Disease, 2022
Ivermectin is a widely used antiparasitic drug and shows promising anticancer activity in various cancer types. Although multiple signaling pathways modulated by ivermectin have been identified in tumor cells, few studies have focused on the exact target
Shidong Lv   +7 more
doaj   +1 more source

Potential metabolic resistance mechanisms to ivermectin in Anopheles gambiae: a synergist bioassay study

open access: yesParasites & Vectors, 2021
Background Despite remarkable success obtained with current malaria vector control strategies in the last 15 years, additional innovative measures will be needed to achieve the ambitious goals for malaria control set for 2030 by the World Health ...
Patricia Nicolas   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy